The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer’s Disease Pathology
Abstract
:1. Introduction
2. The Alzheimer’s Disease Pathology
3. The Entorhinal Cortex as Starting Point
3.1. Selective Neuronal Vulnerability of the Human Entorhinal Cortex
3.2. The Entorhinal Cortex during Physiological Aging
4. The Entorhinal Cortex in AD
4.1. Early Bioenergetic Defects
4.2. ATP Synthase as the Key Target of AD
4.3. Advanced Effects in the Early Stage Resulting from Mitochondrial Dysfunction and Oxidative-Derived Damage
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Organisation, U.N. World population ageing 1950–2050. Popul. Dev. Rev. 2002, XLIX, 483p. [Google Scholar]
- The Centers for Disease Control and Prevention. Public health and aging: Trends in aging-United States and worldwide. JAMA 2003, 289, 1371–1373. [Google Scholar] [CrossRef] [Green Version]
- Ferri, C.P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005, 366, 2112–2117. [Google Scholar] [CrossRef]
- Wimo, A.; Winblad, B.; Aguero-Torres, H.; von Strauss, E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 2003, 17, 63–67. [Google Scholar] [CrossRef]
- Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H.M. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement. 2007, 3, 186–191. [Google Scholar] [CrossRef] [Green Version]
- Lobo, A.; Launer, L.J.; Fratiglioni, L.; Andersen, K.; Di Carlo, A.; Breteler, M.M.; Copeland, J.R.; Dartigues, J.F.; Jagger, C.; Martinez-Lage, J.; et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 2000, 54, S4–S9. [Google Scholar] [PubMed]
- Plassman, B.L.; Langa, K.M.; Fisher, G.G.; Heeringa, S.G.; Weir, D.R.; Ofstedal, M.B.; Burke, J.R.; Hurd, M.D.; Potter, G.G.; Rodgers, W.L.; et al. Prevalence of dementia in the United States: The aging, demographics, and memory study. Neuroepidemiology 2007, 29, 125–132. [Google Scholar] [CrossRef]
- von Strauss, E.; Viitanen, M.; De Ronchi, D.; Winblad, B.; Fratiglioni, L. Aging and the occurrence of dementia: Findings from a population-based cohort with a large sample of nonagenarians. Arch. Neurol. 1999, 56, 587. [Google Scholar] [CrossRef]
- Corrada, M.M.; Brookmeyer, R.; Berlau, D.; Paganini-Hill, A.; Kawas, C.H. Prevalence of dementia after age 90: Results from the 90+ study. Neurology 2008, 71, 337–343. [Google Scholar] [CrossRef] [PubMed]
- Kawas, C.; Gray, S.; Brookmeyer, R.; Fozard, J.; Zonderman, A. Age-specific incidence rates of Alzheimer’s disease: The Baltimore longitudinal study of aging. Neurology 2000, 54, 2072–2077. [Google Scholar] [CrossRef] [PubMed]
- Kukull, W.A.; Higdon, R.; Bowen, J.D.; McCormick, W.C.; Teri, L.; Schellenberg, G.D.; van Belle, G.; Jolley, L.; Larson, E.B. Dementia and Alzheimer disease incidence: A prospective cohort study. Arch. Neurol. 2002, 59, 1737. [Google Scholar] [CrossRef] [Green Version]
- Jorm, A.F.; Jolley, D. The incidence of dementia: A meta-analysis. Neurology 1998, 51, 728–733. [Google Scholar] [CrossRef]
- Miech, R.A.; Breitner, J.C.S.; Zandi, P.P.; Khachaturian, A.S.; Anthony, J.C.; Mayer, L. Incidence of AD may decline in the early 90s for men, later for women: The Cache Country study. Neurology 2002, 58, 209–218. [Google Scholar] [CrossRef]
- Pamplona, R.; Jové, M.; Mota-Martorell, N.; Barja, G. Is the NDUFV2 subunit of the hydrophilic complex I domain a key determinant of animal longevity? FEBS J. 2021, febs.15714. [Google Scholar] [CrossRef]
- Mattson, M.P.; Magnus, T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 2006, 7, 278–294. [Google Scholar] [CrossRef]
- Wang, X.; Michaelis, E.K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2010, 2, 12. [Google Scholar] [CrossRef]
- Jové, M.; Portero-Otín, M.; Naudí, A.; Ferrer, I.; Pamplona, R. Metabolomics of humanbrain aging and age-related neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2014, 73, 640–657. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naudí, A.; Cabré, R.; Jové, M.; Ayala, V.; Gonzalo, H.; Portero-Otín, M.; Ferrer, I.; Pamplona, R. Lipidomics of human brain aging and Alzheimer’s disease pathology. Int. Rev. Neurobiol. 2015, 122, 133–189. [Google Scholar] [PubMed]
- Cabré, R.; Jové, M.; Naudí, A.; Ayala, V.; Piñol-Ripoll, G.; Gil-Villar, M.P.; Dominguez-Gonzalez, M.; Obis, È.; Berdun, R.; Mota-Martorell, N.; et al. Specific metabolomics adaptations define a differential regional vulnerability in the adult human cerebral cortex. Front. Mol. Neurosci. 2016, 9, 138. [Google Scholar] [CrossRef] [PubMed]
- Naudí, A.; Cabré, R.; Ayala, V.; Jové, M.; Mota-Martorell, N.; Portero-Otín, M.; Pamplona, R. Region-specific vulnerability to lipid peroxidation and evidence of neuronal mechanisms for polyunsaturated fatty acid biosynthesis in the healthy adult human central nervous system. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2017, 1862. [Google Scholar] [CrossRef] [PubMed]
- Cobley, J.N.; Fiorello, M.L.; Bailey, D.M. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018, 15, 490–503. [Google Scholar] [CrossRef]
- Lu, T.; Aron, L.; Zullo, J.; Pan, Y.; Kim, H.; Chen, Y.; Yang, T.-H.; Kim, H.-M.; Drake, D.; Liu, X.S.; et al. REST and stress resistance in ageing and Alzheimer’s disease. Nature 2014, 507, 448–454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cabré, R.; Naudí, A.; Dominguez-Gonzalez, M.; Ayala, V.; Jové, M.; Mota-Martorell, N.; Piñol-Ripoll, G.; Gil-Villar, M.P.; Rué, M.; Portero-Otín, M.; et al. Sixty years old is the breakpoint of human frontal cortex aging. Free Radic. Biol. Med. 2017, 103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795. [Google Scholar] [CrossRef] [PubMed]
- Desai, R.; East, D.A.; Hardy, L.; Faccenda, D.; Rigon, M.; Crosby, J.; Alvarez, M.S.; Singh, A.; Mainenti, M.; Hussey, L.K.; et al. Mitochondria form contact sites with the nucleus to couple prosurvival retrograde response. Sci. Adv. 2020, 6, eabc9955. [Google Scholar] [CrossRef] [PubMed]
- Karakaidos, P.; Rampias, T. Mitonuclear interactions in the maintenance of mitochondrial integrity. Life 2020, 10, 173. [Google Scholar] [CrossRef] [PubMed]
- Picard, M.; Sandi, C. The social nature of mitochondria: Implications for human health. Neurosci. Biobehav. Rev. 2021, 120, 595–610. [Google Scholar] [CrossRef]
- Johri, A.; Beal, M.F. Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 2012, 342, 619–630. [Google Scholar] [CrossRef] [Green Version]
- Bose, A.; Beal, M.F. Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem. 2016, 139, 216–231. [Google Scholar] [CrossRef]
- Trinh, D.; Israwi, A.R.; Arathoon, L.R.; Gleave, J.A.; Nash, J.E. The multi-faceted role of mitochondria in the pathology of Parkinson’s disease. J. Neurochem. 2021, 156, 715–752. [Google Scholar] [CrossRef]
- Dionísio, P.A.; Amaral, J.D.; Rodrigues, C.M.P. Oxidative stress and regulated cell death in Parkinson’s disease. Ageing Res. Rev. 2021, 67, 101263. [Google Scholar] [CrossRef] [PubMed]
- Malpartida, A.B.; Williamson, M.; Narendra, D.P.; Wade-Martins, R.; Ryan, B.J. Mitochondrial dysfunction and mitophagy in Parkinson’s disease: From mechanism to therapy. Trends Biochem. Sci. 2021, 46, 329–343. [Google Scholar] [CrossRef] [PubMed]
- Duyckaerts, C. Disentangling Alzheimer’s disease. Lancet Neurol. 2011, 10, 774–775. [Google Scholar] [CrossRef]
- Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239–259. [Google Scholar] [CrossRef]
- Braak, E.; Griffing, K.; Arai, K.; Bohl, J.; Bratzke, H.; Braak, H. Neuropathology of Alzheimer’s disease: What is new since A. Alzheimer? Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249, S14–S22. [Google Scholar] [CrossRef]
- Grinberg, L.T.; Rüb, U.; Ferretti, R.E.L.; Nitrini, R.; Farfel, J.M.; Polichiso, L.; Gierga, K.; Jacob-Filho, W.; Heinsen, H. Brazilian Brain Bank Study Group The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset? Neuropathol. Appl. Neurobiol. 2009, 35, 406–416. [Google Scholar] [CrossRef]
- Simic, G.; Stanic, G.; Mladinov, M.; Jovanov-Milosevic, N.; Kostovic, I.; Hof, P.R. Does Alzheimer’s disease begin in the brainstem? Neuropathol. Appl. Neurobiol. 2009, 35, 532–554. [Google Scholar] [CrossRef] [Green Version]
- Braak, H.; Thal, D.R.; Ghebremedhin, E.; Del Tredici, K. Stages of the pathologic process in Alzheimer disease: Age categoriesfrom 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011, 70, 960–969. [Google Scholar] [CrossRef]
- Thal, D.R.; Rüb, U.; Orantes, M.; Braak, H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58, 1791–1800. [Google Scholar] [CrossRef]
- Lewandowski, C.T.; Maldonado Weng, J.; LaDu, M.J. Alzheimer’s disease pathology in APOE transgenic mouse models: The who, what, when, where, why, and how. Neurobiol. Dis. 2020, 139, 104811. [Google Scholar] [CrossRef]
- Price, J.L.; McKeel, D.W.; Buckles, V.D.; Roe, C.M.; Xiong, C.; Grundman, M.; Hansen, L.A.; Petersen, R.C.; Parisi, J.E.; Dickson, D.W.; et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 2009, 30, 1026–1036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Markesbery, W.R. Neuropathologic alterations in mild cognitive impairment: A review. J. Alzheimer’s Dis. 2010, 19, 221–228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nelson, P.T.; Alafuzoff, I.; Bigio, E.H.; Bouras, C.; Braak, H.; Cairns, N.J.; Castellani, R.J.; Crain, B.J.; Davies, P.; Tredici, K.; et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71, 362–381. [Google Scholar] [CrossRef]
- Ohm, T.G.; Müller, H.; Braak, H.; Bohl, J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 1995, 64, 209–217. [Google Scholar] [CrossRef]
- Braak, H.; Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18, 351–357. [Google Scholar] [CrossRef]
- Ferrer, I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog. Neurobiol. 2012, 97, 38–51. [Google Scholar] [CrossRef]
- Selkoe, D.J. Preventing Alzheimer’s disease. Science 2012, 337, 1488–1492. [Google Scholar] [CrossRef] [Green Version]
- McGeer, P.L.; McGeer, E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol. 2013, 126, 479–497. [Google Scholar] [CrossRef]
- Canto, C.B.; Wouterlood, F.G.; Witter, M.P. What does the anatomical organization of the entorhinal cortex tell us? Neural Plast. 2008, 2008, 1–18. [Google Scholar] [CrossRef] [Green Version]
- Mink, J.W.; Blumenschine, R.J.; Adams, D.B. Ratio of central nervous system to body metabolism in vertebrates: Its constancy and functional basis. Am. J. Physiol. Integr. Comp. Physiol. 1981, 241, R203–R212. [Google Scholar] [CrossRef]
- Caceres, M.; Lachuer, J.; Zapala, M.A.; Redmond, J.C.; Kudo, L.; Geschwind, D.H.; Lockhart, D.J.; Preuss, T.M.; Barlow, C. Elevated gene expression levels distinguish human from non-human primate brains. Proc. Natl. Acad. Sci. USA 2003, 100, 13030–13035. [Google Scholar] [CrossRef] [Green Version]
- Uddin, M.; Wildman, D.E.; Liu, G.; Xu, W.; Johnson, R.M.; Hof, P.R.; Kapatos, G.; Grossman, L.I.; Goodman, M. Sister grouping of chimpanzees and humans as revealed by genome-wide phylogenetic analysis of brain gene expression profiles. Proc. Natl. Acad. Sci. USA 2004, 101, 2957–2962. [Google Scholar] [CrossRef] [Green Version]
- Fu, X.; Giavalisco, P.; Liu, X.; Catchpole, G.; Fu, N.; Ning, Z.-B.; Guo, S.; Yan, Z.; Somel, M.; Paabo, S.; et al. Rapid metabolic evolution in human prefrontal cortex. Proc. Natl. Acad. Sci. USA 2011, 108, 6181–6186. [Google Scholar] [CrossRef] [Green Version]
- Somel, M.; Liu, X.; Khaitovich, P. Human brain evolution: Transcripts, metabolites and their regulators. Nat. Rev. Neurosci. 2013, 14, 112–127. [Google Scholar] [CrossRef]
- Hawrylycz, M.J.; Lein, E.S.; Guillozet-Bongaarts, A.L.; Shen, E.H.; Ng, L.; Miller, J.A.; van de Lagemaat, L.N.; Smith, K.A.; Ebbert, A.; Riley, Z.L.; et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012, 489, 391–399. [Google Scholar] [CrossRef]
- Jové, M.; Naudí, A.; Ramírez-Núñez, O.; Portero-Otín, M.; Selman, C.; Withers, D.J.; Pamplona, R. Caloric restriction reveals a metabolomic and lipidomic signature in liver of male mice. Aging Cell 2014, 13, 828–837. [Google Scholar] [CrossRef] [PubMed]
- Rakic, P.; Nowakowski, R.S. The time of origin of neurons in the hippocampal region of the rhesus monkey. J. Comp. Neurol. 1981, 196, 99–128. [Google Scholar] [CrossRef] [PubMed]
- Stranahan, A.M.; Mattson, M.P. Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer’s disease. Neural Plast. 2010, 2010, 108190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hevner, R.F.; Wong-Riley, M.T. Entorhinal cortex of the human, monkey, and rat: Metabolic map as revealed by cytochrome oxidase. J. Comp. Neurol. 1992, 326, 451–469. [Google Scholar] [CrossRef]
- Buckmaster, P.S.; Alonso, A.; Canfield, D.R.; Amaral, D.G. Dendritic morphology, local circuitry, and intrinsic electrophysiology of principal neurons in the entorhinal cortex of macaque monkeys. J. Comp. Neurol. 2004, 470, 317–329. [Google Scholar] [CrossRef]
- Liang, W.S.; Dunckley, T.; Beach, T.G.; Grover, A.; Mastroeni, D.; Walker, D.G.; Caselli, R.J.; Kukull, W.A.; McKeel, D.; Morris, J.C.; et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol. Genomics 2007, 28, 311–322. [Google Scholar] [CrossRef] [PubMed]
- Locasale, J.W. Serine, glycine and one-carbon units: Cancer metabolism in full circle. Nat. Rev. Cancer 2013, 13, 572–583. [Google Scholar] [CrossRef] [Green Version]
- Miller, A.L. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern. Med. Rev. 2003, 8, 7–19. [Google Scholar]
- Pamplona, R.; Barja, G. Mitochondrial oxidative stress, aging and caloric restriction: The protein and methionine connection. Biochim. Biophys. Acta Bioenerg. 2006, 1757, 496–508. [Google Scholar] [CrossRef] [Green Version]
- Pamplona, R.; Barja, G. An evolutionary comparative scan for longevity-related oxidative stress resistance mechanisms in homeotherms. Biogerontology 2011, 12, 409–435. [Google Scholar] [CrossRef]
- Naudí, A.; Caro, P.; Jové, M.; Gómez, J.; Boada, J.; Ayala, V.; Portero-Otín, M.; Barja, G.; Pamplona, R. Methionine restriction decreases endogenous oxidative molecular damage and increases mitochondrial biogenesis and uncoupling protein 4 in rat brain. Rejuvenation Res. 2007, 10, 473–484. [Google Scholar] [CrossRef]
- Garelick, M.G.; Kennedy, B.K. TOR on the brain. Exp. Gerontol. 2011, 46, 155–163. [Google Scholar] [CrossRef] [PubMed]
- Bockaert, J.; Marin, P. mTOR in Brain Physiology and Pathologies. Physiol. Rev. 2015, 95, 1157–1187. [Google Scholar] [CrossRef]
- Perluigi, M.; Di Domenico, F.; Butterfield, D.A. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol. Dis. 2015, 84, 39–49. [Google Scholar] [CrossRef]
- Salat, D.H. Thinning of the cerebral cortex in aging. Cereb. Cortex 2004, 14, 721–730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lemaitre, H.; Goldman, A.L.; Sambataro, F.; Verchinski, B.A.; Meyer-Lindenberg, A.; Weinberger, D.R.; Mattay, V.S. Normal age-related brain morphometric changes: Nonuniformity across cortical thickness, surface area and gray matter volume? Neurobiol. Aging 2012, 33, 617.e1–617.e9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feng, X.; Guo, J.; Sigmon, H.C.; Sloan, R.P.; Brickman, A.M.; Provenzano, F.A.; Small, S.A. Brain regions vulnerable and resistant to aging without Alzheimer’s disease. PLoS ONE 2020, 15, e0234255. [Google Scholar] [CrossRef] [PubMed]
- Morrison, J.H.; Hof, P. Life and death of neurons in the aging brain. Science 1997, 278, 412–419. [Google Scholar] [CrossRef] [Green Version]
- Insausti, R.; Insausti, A.M.; Sobreviela, M.T.; Salinas, A.; Martínez-Peñuela, J.M. Human medial temporal lobe in aging: Anatomical basis of memory preservation. Microsc. Res. Tech. 1998, 43, 8–15. [Google Scholar] [CrossRef]
- Raz, N.; Lindenberger, U.; Rodrigue, K.M.; Kennedy, K.M.; Head, D.; Williamson, A.; Dahle, C.; Gerstorf, D.; Acker, J.D. Regional brain changes in aging healthy adults: General trends, individual differences and modifiers. Cereb. Cortex 2005, 15, 1676–1689. [Google Scholar] [CrossRef]
- Donix, M.; Burggren, A.C.; Scharf, M.; Marschner, K.; Suthana, N.A.; Siddarth, P.; Krupa, A.K.; Jones, M.; Martin-Harris, L.; Ercoli, L.M.; et al. APOE associated hemispheric asymmetry of entorhinal cortical thickness in aging and Alzheimer’s disease. Psychiatry Res. Neuroimaging 2013, 214, 212–220. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, J.; Sachdev, P.; Lipnicki, D.M.; Zhang, H.; Liu, T.; Zhu, W.; Suo, C.; Zhuang, L.; Crawford, J.; Reppermund, S.; et al. A longitudinal study of brain atrophy over two years in community-dwelling older individuals. Neuroimage 2014, 86, 203–211. [Google Scholar] [CrossRef]
- Fjell, A.M.; Westlye, L.T.; Grydeland, H.; Amlien, I.; Espeseth, T.; Reinvang, I.; Raz, N.; Dale, A.M.; Walhovd, K.B. Accelerating cortical thinning: Unique to dementia or universal in aging? Cereb. Cortex 2014, 24, 919–934. [Google Scholar] [CrossRef] [Green Version]
- Hasan, K.M.; Mwangi, B.; Cao, B.; Keser, Z.; Tustison, N.J.; Kochunov, P.; Frye, R.E.; Savatic, M.; Soares, J. Entorhinal cortex thickness across the human lifespan. J. Neuroimaging 2016, 26, 278–282. [Google Scholar] [CrossRef] [Green Version]
- Kurth, F.; Cherbuin, N.; Luders, E. The impact of aging on subregions of the hippocampal complex in healthy adults. Neuroimage 2017, 163, 296–300. [Google Scholar] [CrossRef] [Green Version]
- Raz, N.; Rodrigue, K.M.; Head, D.; Kennedy, K.M.; Acker, J.D. Differential aging of the medial temporal lobe: A study of a five-year change. Neurology 2004, 62, 433–438. [Google Scholar] [CrossRef]
- Wang, S.-Y.; Wang, W.-J.; Liu, J.-Q.; Song, Y.-H.; Li, P.; Sun, X.-F.; Cai, G.-Y.; Chen, X.-M. Methionine restriction delays senescence and suppresses the senescence-associated secretory phenotype in the kidney through endogenous hydrogen sulfide. Cell Cycle 2019, 18, 1573–1587. [Google Scholar] [CrossRef]
- Olsen, R.K.; Yeung, L.-K.; Noly-Gandon, A.; D’Angelo, M.C.; Kacollja, A.; Smith, V.M.; Ryan, J.D.; Barense, M.D. Human anterolateral entorhinal cortex volumes are associated with cognitive decline in aging prior to clinical diagnosis. Neurobiol. Aging 2017, 57, 195–205. [Google Scholar] [CrossRef] [PubMed]
- Reagh, Z.M.; Noche, J.A.; Tustison, N.J.; Delisle, D.; Murray, E.A.; Yassa, M.A. Functional imbalance of anterolateral entorhinal cortex and hippocampal dentate/CA3 underlies age-related object pattern separation deficits. Neuron 2018, 97, 1187–1198.e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Delgado-González, J.C.; Rosa-Prieto, C.; Tarruella-Hernández, D.L.; Vallejo-Calcerrada, N.; Cebada-Sánchez, S.; Insausti, R.; Artacho-Pérula, E. Neuronal volume of the hippocampal regions in ageing. J. Anat. 2020, 237, 301–310. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Pinilla, E.; Ordóñez, C.; del Valle, E.; Navarro, A.; Tolivia, J. Regional and gender study of neuronal density in brain during aging and in Alzheimer’s disease. Front. Aging Neurosci. 2016, 8. [Google Scholar] [CrossRef]
- Gómez-Isla, T.; Price, J.L.; McKeel, D.W., Jr.; Morris, J.C.; Growdon, J.H.; Hyman, B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J. Neurosci. 1996, 16, 4491–4500. [Google Scholar] [CrossRef]
- Simic, G.; Bexheti, S.; Kelovic, Z.; Kos, M.; Grbic, K.; Hof, P.R.; Kostovic, I. Hemispheric asymmetry, modular variability and age-related changes in the human entorhinal cortex. Neuroscience 2005, 130, 911–925. [Google Scholar] [CrossRef]
- Hancock, S.E.; Friedrich, M.G.; Mitchell, T.W.; Truscott, R.J.W.; Else, P.L. The phospholipid composition of the human entorhinal cortex remains relatively stable over 80 years of adult aging. GeroScience 2017, 39, 73–82. [Google Scholar] [CrossRef] [Green Version]
- Pamplona, R.; Portero-Otın, M.; Sanz, A.; Requena, J.; Barja, G. Modification of the longevity-related degree of fatty acid unsaturation modulates oxidative damage to proteins and mitochondrial DNA in liver and brain. Exp. Gerontol. 2004, 39, 725–733. [Google Scholar] [CrossRef]
- Domínguez-González, M.; Puigpinós, M.; Jové, M.; Naudi, A.; Portero-Otín, M.; Pamplona, R.; Ferrer, I. Regional vulnerability to lipoxidative damage and inflammation in normal human brain aging. Exp. Gerontol. 2018, 111, 218–228. [Google Scholar] [CrossRef]
- López-González, I.; Tebé Cordomí, C.; Ferrer, I. Regional gene expression of inflammation and oxidative stress responses does not predict neurodegeneration in aging. J. Neuropathol. Exp. Neurol. 2017. [Google Scholar] [CrossRef] [Green Version]
- Dickerson, B.C.; Bakkour, A.; Salat, D.H.; Feczko, E.; Pacheco, J.; Greve, D.N.; Grodstein, F.; Wright, C.I.; Blacker, D.; Rosas, H.D.; et al. The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19, 497–510. [Google Scholar] [CrossRef] [Green Version]
- Whitwell, J.L.; Dickson, D.W.; Murray, M.E.; Weigand, S.D.; Tosakulwong, N.; Senjem, M.L.; Knopman, D.S.; Boeve, B.F.; Parisi, J.E.; Petersen, R.C.; et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: A case-control study. Lancet Neurol. 2012, 11, 868–877. [Google Scholar] [CrossRef] [Green Version]
- Cho, Y.; Seong, J.-K.; Jeong, Y.; Shin, S.Y. Individual subject classification for Alzheimer’s disease based on incremental learning using a spatial frequency representation of cortical thickness data. Neuroimage 2012, 59, 2217–2230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guzman, V.A.; Carmichael, O.T.; Schwarz, C.; Tosto, G.; Zimmerman, M.E.; Brickman, A.M. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimer’s Dement. 2013, 9, S124–S131. [Google Scholar] [CrossRef] [Green Version]
- Mah, L.; Binns, M.A.; Steffens, D.C. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial remporal atrophy and predict conversion to Alzheimer disease. Am. J. Geriatr. Psychiatry 2015, 23, 466–476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Varon, D.; Barker, W.; Loewenstein, D.; Greig, M.; Bohorquez, A.; Santos, I.; Shen, Q.; Harper, M.; Vallejo-Luces, T.; Duara, R. Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort: Baseline diagnosis and the prediction of MCI outcome. Int. J. Geriatr. Psychiatry 2015, 30, 192–200. [Google Scholar] [CrossRef]
- Devanand, D.P.; Pradhaban, G.; Liu, X.; Khandji, A.; De Santi, S.; Segal, S.; Rusinek, H.; Pelton, G.H.; Honig, L.S.; Mayeux, R.; et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology 2007, 68, 828–836. [Google Scholar] [CrossRef] [PubMed]
- La Joie, R.; Perrotin, A.; Barre, L.; Hommet, C.; Mezenge, F.; Ibazizene, M.; Camus, V.; Abbas, A.; Landeau, B.; Guilloteau, D.; et al. Region-specific hierarchy between atrophy, hypometabolism, and β-Amyloid (Aβ) load in Alzheimer’s disease dementia. J. Neurosci. 2012, 32, 16265–16273. [Google Scholar] [CrossRef] [Green Version]
- Younes, L.; Albert, M.; Miller, M.I. Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer’s disease. NeuroImage Clin. 2014, 5, 178–187. [Google Scholar] [CrossRef] [Green Version]
- Miller, M.I.; Ratnanather, J.T.; Tward, D.J.; Brown, T.; Lee, D.S.; Ketcha, M.; Mori, K.; Wang, M.-C.; Mori, S.; Albert, M.S.; et al. Network neurodegeneration in Alzheimer’s disease via MRI based shape diffeomorphometry and high-field atlasing. Front. Bioeng. Biotechnol. 2015, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kulason, S.; Xu, E.; Tward, D.J.; Bakker, A.; Albert, M.; Younes, L.; Miller, M.I. Entorhinal and transentorhinal atrophy in preclinical Alzheimer’s disease. Front. Neurosci. 2020, 14. [Google Scholar] [CrossRef] [PubMed]
- Atiya, M.; Hyman, B.T.; Albert, M.S.; Killiany, R. Structural magnetic resonance imaging in established and prodromal Alzheimer disease: A review. Alzheimer Dis. Assoc. Disord. 2003, 17, 177–195. [Google Scholar] [CrossRef] [PubMed]
- Kantarci, K.; Jack, C.R. Neuroimaging in Alzheimer disease: An evidence-based review. Neuroimaging Clin. N. Am. 2003, 13, 197–209. [Google Scholar] [CrossRef]
- Jack, C.R.; Shiung, M.M.; Gunter, J.L.; O’Brien, P.C.; Weigand, S.D.; Knopman, D.S.; Boeve, B.F.; Ivnik, R.J.; Smith, G.E.; Cha, R.H.; et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004, 62, 591–600. [Google Scholar] [CrossRef]
- Csernansky, J.G.; Wang, L.; Swank, J.; Miller, J.P.; Gado, M.; McKeel, D.; Miller, M.I.; Morris, J.C. Preclinical detection of Alzheimer’s disease: Hippocampal shape and volume predict dementia onset in the elderly. Neuroimage 2005, 25, 783–792. [Google Scholar] [CrossRef] [PubMed]
- den Heijer, T.; Geerlings, M.I.; Hoebeek, F.E.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M.B. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch. Gen. Psychiatry 2006, 63, 57. [Google Scholar] [CrossRef] [PubMed]
- Apostolova, L.G.; Mosconi, L.; Thompson, P.M.; Green, A.E.; Hwang, K.S.; Ramirez, A.; Mistur, R.; Tsui, W.H.; de Leon, M.J. Subregional hippocampal atrophy predicts Alzheimer’s dementia in the cognitively normal. Neurobiol. Aging 2010, 31, 1077–1088. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dickerson, B.C.; Stoub, T.R.; Shah, R.C.; Sperling, R.A.; Killiany, R.J.; Albert, M.S.; Hyman, B.T.; Blacker, D.; DeToledo-Morrell, L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011, 76, 1395–1402. [Google Scholar] [CrossRef] [Green Version]
- Miller, M.I.; Younes, L.; Ratnanather, J.T.; Brown, T.; Trinh, H.; Postell, E.; Lee, D.S.; Wang, M.-C.; Mori, S.; O’Brien, R.; et al. The diffeomorphometry of temporal lobe structures in preclinical Alzheimer’s disease. NeuroImage Clin. 2013, 3, 352–360. [Google Scholar] [CrossRef] [Green Version]
- Soldan, A.; Pettigrew, C.; Lu, Y.; Wang, M.; Selnes, O.; Albert, M.; Brown, T.; Ratnanather, J.T.; Younes, L.; Miller, M.I. Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer’s disease. Hum. Brain Mapp. 2015, 36, 2826–2841. [Google Scholar] [CrossRef] [Green Version]
- Pettigrew, C.; Soldan, A.; Zhu, Y.; Wang, M.-C.; Moghekar, A.; Brown, T.; Miller, M.; Albert, M. Cortical thickness in relation to clinical symptom onset in preclinical AD. NeuroImage Clin. 2016, 12, 116–122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kidd, M. Alzheimer’s Disease—An electron microscopical study. Brain 1964, 87, 307–320. [Google Scholar] [CrossRef] [PubMed]
- Luse, S.A.; Smith, K.R. The ultrastructure of senile plaques. Am. J. Pathol. 1964, 44, 553–563. [Google Scholar] [PubMed]
- Terry, R.D.; Gonatas, N.K.; Weiss, M. Ultrastructural studies in Alzheimer’s presenile demientia. Am. J. Pathol. 1964, 44, 269–297. [Google Scholar] [PubMed]
- Johnson, A.B.; Blum, N.R. Nucleoside phosphatase activities associated with the tangles and plaques of Alzheimer’s disease: A histochemical study of natural and experimental neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 1970, 29, 463–478. [Google Scholar] [CrossRef] [PubMed]
- Wiśniewski, H.; Terry, R.D.; Hirano, A. Neurofibrillary pathology. J. Neuropathol. Exp. Neurol. 1970, 29, 163–176. [Google Scholar] [CrossRef] [PubMed]
- Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; et al. Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci. 2001, 21, 3017–3023. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baloyannis, S.J. Mitochondrial alterations in Alzheimer’s disease. J. Alzheimer’s Dis. 2006, 9, 119–126. [Google Scholar] [CrossRef] [PubMed]
- Ferris, S.H.; de Leon, M.J.; Wolf, A.P.; Farkas, T.; Christman, D.R.; Reisberg, B.; Fowler, J.S.; MacGregor, R.; Goldman, A.; George, A.E.; et al. Positron emission tomography in the study of aging and senile dementia. Neurobiol. Aging 1980, 1, 127–131. [Google Scholar] [CrossRef]
- Foster, N.L.; Chase, T.N.; Fedio, P.; Patronas, N.J.; Brooks, R.A.; Chiro, G.D. Alzheimer’s disease: Focal cortical changes shown by positron emission tomography. Neurology 1983, 33, 961. [Google Scholar] [CrossRef] [PubMed]
- de Leon, M.J.; George, A.E.; Ferris, S.H.; Rosenbloom, S.; Christman, D.R.; Gentes, C.I.; Reisberg, B.; Kricheff, I.I.; Wolf, A.P. Regional correlation of PET and CT in senile dementia of the Alzheimer type. AJNR. Am. J. Neuroradiol. 1983, 4, 553–556. [Google Scholar] [PubMed]
- Frackowiak, R.S.J.; Pozilli, C.J.; Legg, N.D.; Boulay, G.H.; Marshall, J.; Lenzi, G.L.; Jones, T. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981, 104, 753–778. [Google Scholar] [CrossRef]
- Fukuyama, H.; Ogawa, M.; Yamauchi, H.; Yamaguchi, S.; Kimura, J.; Yonekura, Y.; Konishi, J. Altered cerebral energy metabolism in Alzheimer’s disease: A PET study. J. Nucl. Med. 1994, 35, 1–6. [Google Scholar]
- Blass, J.P.; Zemcov, A. Alzheimer’s disease. A metabolic systems degeneration? Neurochem. Pathol. 1984, 2, 103–114. [Google Scholar] [CrossRef] [PubMed]
- Hoyer, S. Abnormalities in brain glucose utilization and its impact on cellular and molecular mechanisms in sporadic dementia of Alzheimer type. Ann. N. Y. Acad. Sci. 1993, 695, 77–80. [Google Scholar] [CrossRef] [PubMed]
- Swerdlow, R.H. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J. Alzheimer’s Dis. 2018, 62, 1403–1416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38, 357–366. [Google Scholar] [CrossRef]
- Sorbi, S.; Bird, E.D.; Blass, J.P. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol. 1983, 13, 72–78. [Google Scholar] [CrossRef]
- Gibson, G.E.; Sheu, K.-F.R.; Blass, J.P.; Baker, A.; Carlson, K.C.; Harding, B.; Perrino, P. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch. Neurol. 1988, 45, 836–840. [Google Scholar] [CrossRef]
- Parker, W.D.; Filley, C.M.; Parks, J.K. Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology 1990, 40, 1302. [Google Scholar] [CrossRef] [PubMed]
- Gibson, G.E.; Starkov, A.; Blass, J.P.; Ratan, R.R.; Beal, M.F. Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2010, 1802, 122–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghosh, S.S.; Swerdlow, R.H.; Miller, S.W.; Sheeman, B.; Parker, W.D.; Davis, R.E. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer’s disease and Parkinson’s disease. Ann. N. Y. Acad. Sci. 1999, 893, 176–191. [Google Scholar] [CrossRef]
- Khan, S.M.; Cassarino, D.S.; Abramova, N.N.; Keeney, P.M.; Borland, M.K.; Trimmer, P.A.; Krebs, C.T.; Bennett, J.C.; Parks, J.K.; Swerdlow, R.H.; et al. Alzheimer’s disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann. Neurol. 2000, 48, 148–155. [Google Scholar] [CrossRef]
- Trimmer, P.A.; Swerdlow, R.H.; Parks, J.K.; Keeney, P.; Bennett, J.P.; Miller, S.W.; Davis, R.E.; Parker, W.D. Abnormal mitochondrial morphology in sporadic Parkinson’s and Alzheimer’s disease cybrid cell lines. Exp. Neurol. 2000, 162, 37–50. [Google Scholar] [CrossRef]
- Terni, B.; Boada, J.; Portero-Otin, M.; Pamplona, R.; Ferrer, I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer’s disease pathology. Brain Pathol. 2010, 20, 222–233. [Google Scholar] [CrossRef] [PubMed]
- Armand-Ugon, M.; Ansoleaga, B.; Berjaoui, S.; Ferrer, I. Reduced mitochondrial activity is early and steady in the entorhinal cortex but it is mainly unmodified in the frontal cortex in Alzheimer’s disease. Curr. Alzheimer Res. 2017, 14. [Google Scholar] [CrossRef] [PubMed]
- Cadonic, C.; Sabbir, M.G.; Albensi, B.C. Mechanisms of mitochondrial dysfunction in Alzheimer’s disease. Mol. Neurobiol. 2016, 53, 6078–6090. [Google Scholar] [CrossRef]
- Wang, W.; Zhao, F.; Ma, X.; Perry, G.; Zhu, X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances. Mol. Neurodegener. 2020, 15, 30. [Google Scholar] [CrossRef]
- Pamplona, R.; Dalfó, E.; Ayala, V.; Bellmunt, M.J.; Prat, J.; Ferrer, I.; Portero-Otín, M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 2005, 280, 21522–21530. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Wang, W.; Li, L.; Perry, G.; Lee, H.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim. Biophys. Acta Mol. Basis Dis. 2014, 1842, 1240–1247. [Google Scholar] [CrossRef] [Green Version]
- Tramutola, A.; Lanzillotta, C.; Perluigi, M.; Butterfield, D.A. Oxidative stress, protein modification and Alzheimer disease. Brain Res. Bull. 2017, 133, 88–96. [Google Scholar] [CrossRef]
- Ferrer, I. Proteomics and lipidomics in the human brain. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2018; pp. 285–302. [Google Scholar]
- Tobore, T.O. On the central role of mitochondria dysfunction and oxidative stress in Alzheimer’s disease. Neurol. Sci. 2019, 40, 1527–1540. [Google Scholar] [CrossRef] [PubMed]
- Butterfield, D.A.; Boyd-Kimball, D. Mitochondrial oxidative and nitrosative stress and Alzheimer disease. Antioxidants 2020, 9, 818. [Google Scholar] [CrossRef] [PubMed]
- Ebanks, B.; Ingram, T.L.; Chakrabarti, L. ATP synthase and Alzheimer’s disease: Putting a spin on the mitochondrial hypothesis. Aging (Albany. NY). 2020, 12, 16647–16662. [Google Scholar] [CrossRef] [PubMed]
- Pinke, G.; Zhou, L.; Sazanov, L.A. Cryo-EM structure of the entire mammalian F-type ATP synthase. Nat. Struct. Mol. Biol. 2020, 27, 1077–1085. [Google Scholar] [CrossRef] [PubMed]
- Jové, M.; Pradas, I.; Dominguez-Gonzalez, M.; Ferrer, I.; Pamplona, R. Lipids and lipoxidation in human brain aging. Mitochondrial ATP-synthase as a key lipoxidation target. Redox Biol. 2019, 23, 101082. [Google Scholar] [CrossRef] [PubMed]
- Nesci, S.; Trombetti, F.; Ventrella, V.; Pagliarani, A. Post-translational modifications of the mitochondrial F1FO-ATPase. Biochim. Biophys. Acta Gen. Subj. 2017, 1861, 2902–2912. [Google Scholar] [CrossRef]
- Domínguez, M.; de Oliveira, E.; Odena, M.A.; Portero, M.; Pamplona, R.; Ferrer, I. Redox proteomic profiling of neuroketal-adducted proteins in human brain: Regional vulnerability at middle age increases in the elderly. Free Radic. Biol. Med. 2016, 95, 1–15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martínez, A.; Portero-Otin, M.; Pamplona, R.; Ferrer, I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol. 2010, 20, 281–297. [Google Scholar] [CrossRef] [PubMed]
- Manavalan, A.; Mishra, M.; Feng, L.; Sze, S.K.; Akatsu, H.; Heese, K. Brain site-specific proteome changes in aging-related dementia. Exp. Mol. Med. 2013, 45, e39. [Google Scholar] [CrossRef] [PubMed]
- Brinkmalm, A.; Brinkmalm, G.; Honer, W.G.; Moreno, J.A.; Jakobsson, J.; Mallucci, G.R.; Zetterberg, H.; Blennow, K.; Öhrfelt, A. Targeting synaptic pathology with a novel affinity mass spectrometry approach. Mol. Cell. Proteom. 2014, 13, 2584–2592. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, R.Y.K.; Etheridge, N.; Dodd, P.R.; Nouwens, A.S. Targeted quantitative analysis of synaptic proteins in Alzheimer’s disease brain. Neurochem. Int. 2014, 75, 66–75. [Google Scholar] [CrossRef] [PubMed]
- Reed, T.; Perluigi, M.; Sultana, R.; Pierce, W.M.; Klein, J.B.; Turner, D.M.; Coccia, R.; Markesbery, W.R.; Butterfield, D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease. Neurobiol. Dis. 2008, 30, 107–120. [Google Scholar] [CrossRef] [PubMed]
- Perluigi, M.; Sultana, R.; Cenini, G.; Di Domenico, F.; Memo, M.; Pierce, W.M.; Coccia, R.; Butterfield, D.A. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer’s disease: Role of lipid peroxidation in Alzheimer’s disease pathogenesis. Proteomics. Clin. Appl. 2009, 3, 682–693. [Google Scholar] [CrossRef] [Green Version]
- Reed, T.T.; Pierce, W.M.; Markesbery, W.R.; Butterfield, D.A. Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res. 2009, 1274, 66–76. [Google Scholar] [CrossRef] [PubMed]
- Di Domenico, F.; Tramutola, A.; Butterfield, D.A. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic. Biol. Med. 2017, 111, 253–261. [Google Scholar] [CrossRef]
- Ottis, P.; Koppe, K.; Onisko, B.; Dynin, I.; Arzberger, T.; Kretzschmar, H.; Requena, J.R.; Silva, C.J.; Huston, J.P.; Korth, C. Human and rat brain lipofuscin proteome. Proteomics 2012, 12, 2445–2454. [Google Scholar] [CrossRef]
- Semick, S.A.; Bharadwaj, R.A.; Collado-Torres, L.; Tao, R.; Shin, J.H.; Deep-Soboslay, A.; Weiss, J.R.; Weinberger, D.R.; Hyde, T.M.; Kleinman, J.E.; et al. Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer’s disease. Acta Neuropathol. 2019, 137, 557–569. [Google Scholar] [CrossRef]
- Ding, B.; Xi, Y.; Gao, M.; Li, Z.; Xu, C.; Fan, S.; He, W. Gene expression profiles of entorhinal cortex in Alzheimer’s disease. Am. J. Alzheimers. Dis. Other Demen. 2014, 29, 526–532. [Google Scholar] [CrossRef]
- Chandrasekaran, K.; Hatanpää, K.; Brady, D.R.; Stoll, J.; Rapoport, S.I. Downregulation of oxidative phosphorylation in Alzheimer disease: Loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Brain Res. 1998, 796, 13–19. [Google Scholar] [CrossRef]
- Cenini, G.; Fiorini, A.; Sultana, R.; Perluigi, M.; Cai, J.; Klein, J.B.; Head, E.; Butterfield, D.A. An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: A proteomics approach. Free Radic. Biol. Med. 2014, 76, 89–95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Butterfield, D.A.; Palmieri, E.M.; Castegna, A. Clinical implications from proteomic studies in neurodegenerative diseases: Lessons from mitochondrial proteins. Expert Rev. Proteom. 2016, 13, 259–274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blanch, M.; Mosquera, J.L.; Ansoleaga, B.; Ferrer, I.; Barrachina, M. Altered mitochondrial DNA methylation pattern in Alzheimer disease–related pathology and in Parkinson disease. Am. J. Pathol. 2016, 186, 385–397. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fernandez-Echevarria, C.; Díaz, M.; Ferrer, I.; Canerina-Amaro, A.; Marin, R. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer’s disease. Neuroscience 2014, 278, 354–366. [Google Scholar] [CrossRef]
- Ansoleaga, B.; Jové, M.; Schlüter, A.; Garcia-Esparcia, P.; Moreno, J.; Pujol, A.; Pamplona, R.; Portero-Otín, M.; Ferrer, I. Deregulation of purine metabolism in Alzheimer’s disease. Neurobiol. Aging 2015, 36, 68–80. [Google Scholar] [CrossRef]
- Kichev, A.; Ilieva, E.V.; Piñol-Ripoll, G.; Podlesniy, P.; Ferrer, I.; Portero-Otín, M.; Pamplona, R.; Espinet, C. Cell death and learning impairment in mice caused by in vitro modified pro-NGF can be related to its increased oxidative modifications in Alzheimer disease. Am. J. Pathol. 2009, 175, 2574–2585. [Google Scholar] [CrossRef] [Green Version]
- Llorens, F.; Thüne, K.; Andrés-Benito, P.; Tahir, W.; Ansoleaga, B.; Hernández-Ortega, K.; Martí, E.; Zerr, I.; Ferrer, I. MicroRNA expression in the locus coeruleus, entorhinal cortex, and hippocampus at early and middle stages of Braak neurofibrillary tangle pathology. J. Mol. Neurosci. 2017, 63, 206–215. [Google Scholar] [CrossRef]
- Terni, B.; Ferrer, I. Abnormal expression and distribution of MMP2 at initial stages of Alzheimer’s disease-related pathology. J. Alzheimer’s Dis. 2015, 46, 461–469. [Google Scholar] [CrossRef]
- Ferrer, I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer’s disease and Creutzfeldt-Jakob’s disease. Neuropathol. Appl. Neurobiol. 2002, 28, 441–451. [Google Scholar] [CrossRef]
- Chan, R.B.; Oliveira, T.G.; Cortes, E.P.; Honig, L.S.; Duff, K.E.; Small, S.A.; Wenk, M.R.; Shui, G.; Di Paolo, G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 2012, 287, 2678–2688. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fabelo, N.; Martín, V.; Marín, R.; Moreno, D.; Ferrer, I.; Díaz, M. Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer’s disease and facilitates APP/BACE1 interactions. Neurobiol. Aging 2014, 35, 1801–1812. [Google Scholar] [CrossRef] [PubMed]
- Xia, J.; Rocke, D.M.; Perry, G.; Ray, M. Differential network analyses of Alzheimer’s disease identify early events in Alzheimer’s disease pathology. Int. J. Alzheimers Dis. 2014, 2014, 1–18. [Google Scholar] [CrossRef] [Green Version]
- Wassall, S.R.; Stillwell, W. Polyunsaturated fatty acid–cholesterol interactions: Domain formation in membranes. Biochim. Biophys. Acta Biomembr. 2009, 1788, 24–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Montesinos, J.; Pera, M.; Larrea, D.; Guardia-Laguarta, C.; Agrawal, R.R.; Velasco, K.R.; Yun, T.D.; Stavrovskaya, I.G.; Xu, Y.; Koo, S.Y.; et al. The Alzheimer’s disease-associated C99 fragment of APP regulates cellular cholesterol trafficking. EMBO J. 2020, 39. [Google Scholar] [CrossRef] [PubMed]
- Pera, M.; Larrea, D.; Guardia-Laguarta, C.; Montesinos, J.; Velasco, K.R.; Agrawal, R.R.; Xu, Y.; Chan, R.B.; Di Paolo, G.; Mehler, M.F.; et al. Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J. 2017, 36, 3356–3371. [Google Scholar] [CrossRef]
- Leng, K.; Li, E.; Eser, R.; Piergies, A.; Sit, R.; Tan, M.; Neff, N.; Li, S.H.; Rodriguez, R.D.; Suemoto, C.K.; et al. Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease. Nat. Neurosci. 2021, 24, 276–287. [Google Scholar] [CrossRef]
- Olajide, O.J.; Suvanto, M.E.; Chapman, C.A. Molecular mechanisms of neurodegeneration in the entorhinal cortex that underlie its selective vulnerability during the pathogenesis of Alzheimer’s disease. Biol. Open 2021, 10, bio056796. [Google Scholar] [CrossRef]
ID (Entry Human) | Protein | Gene | Biological Process | Reference |
---|---|---|---|---|
Q99798 | Aconitate hydratase | ACO2 | Energy metabolism (TCA cycle) | [151,155,156,157,158,159] |
P00367 | Glutamate dehydrogenase 1 | GLUD1 | Energy metabolism (TCA cycle) | [141] |
P40926 | Malate dehydrogenase | MDH2 | Energy metabolism (TCA cycle) | [156,157,158,159] |
P20674 | Cytochrome c oxidase subunit 5a | COX5A | Energy metabolism (ETC) | [159] |
P09622 | Dihydrolipoyl dehydrogenase | DLD | Energy metabolism (ETC) | [151] |
O75489 | NADH dehydrogenase (ubiquinone) iron-sulfur protein 3 | NDUFS3 | Energy metabolism (ETC) | [159] |
P31930 | Ubiquinol-cytochrome c reductase complex core protein 1 | UQCRC1 | Energy metabolism (ETC) | [141] |
P25705 | ATP synthase subunit alpha | ATP5F1A | Energy metabolism (OxPhos) | [137,151,155,156,157,158,159,160] |
P06576 | ATP synthase subunit beta | ATP5F1B | Energy metabolism (OxPhos) | [137,141,160] |
O75947 | ATP synthase subunit d | ATP5H | Energy metabolism (OxPhos) | [159] |
P48047 | ATP synthase subunit o | ATP5PO | Energy metabolism (OxPhos) | [159] |
P12532 | Creatine Kinase U-type | CKMT1A | Energy metabolism (energy transduction) | [159] |
P15104 | Glutamine synthetase | GLUL | Neurotransmission | [141,156,157,158,159] |
P49411 | Elongation factor Tu | TUFM | Proteostasis | [156,157,158,159] |
P10809 | Heat shock protein 60KDa | HSPD1 | Proteostasis | [141,151,159] |
Q99497 | Protein/nucleic acid deglycase DJ-1 | PARK7 | Proteostasis | [151] |
P04179 | Manganese superoxide dismutase | SOD2 | Antioxidants | [156,157,158,159] |
P21796 | Voltage-dependent anion-selective channel protein 1 | VDAC1 | Ion channel | [159] |
Aging | Alzheimer’s Disease |
---|---|
Minor loss of volume, thickness, and surface area | ↓↓ volume and thickness |
↑ neuron body size | Abnormalities in mitochondrial structure and dynamics |
↑ number of astrocytes | Mitochondrial-bioenergetic failure |
Minor changes in fatty acid profile | Loss-of-function of mitochondrial ATP synthase |
Minor changes of the phospholipid profile of mitochondrial and microsomal membranes: ↑ phosphatidycholine content, and ↓ phosphatidylethanolamine (PE) content (but increase PE molecular species containing DHA) | Alterations in lipid metabolism and lipidomic profile of neuronal membrane |
↑ lipoxidation-derived protein adducts | ↑↑ lipid peroxidation and lipoxidation-derived molecular damage |
↑ lipofuscin granule content | Expansion of molecular damage to components belonging to bioenergetics, neurotransmission, cytoskeleton, proteostasis, antioxidants, ion channel, and oxygen metabolism |
No changes in the expression of inflammatory mediators | Alterations of several mitochondrial activities (import of proteins, fusion and fission, mitophagy, cross-talk with other cell compartments) and gene expression |
No loss of neurons | Neuronal death |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jové, M.; Mota-Martorell, N.; Torres, P.; Ayala, V.; Portero-Otin, M.; Ferrer, I.; Pamplona, R. The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer’s Disease Pathology. Life 2021, 11, 388. https://doi.org/10.3390/life11050388
Jové M, Mota-Martorell N, Torres P, Ayala V, Portero-Otin M, Ferrer I, Pamplona R. The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer’s Disease Pathology. Life. 2021; 11(5):388. https://doi.org/10.3390/life11050388
Chicago/Turabian StyleJové, Mariona, Natàlia Mota-Martorell, Pascual Torres, Victoria Ayala, Manuel Portero-Otin, Isidro Ferrer, and Reinald Pamplona. 2021. "The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer’s Disease Pathology" Life 11, no. 5: 388. https://doi.org/10.3390/life11050388
APA StyleJové, M., Mota-Martorell, N., Torres, P., Ayala, V., Portero-Otin, M., Ferrer, I., & Pamplona, R. (2021). The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer’s Disease Pathology. Life, 11(5), 388. https://doi.org/10.3390/life11050388